Mira Pharmaceuticals riporta risultati preclinici per Mira-55 senza effetti collaterali sul SNC simili a THC o rimonabant
MIRA Pharmaceuticals Stock Surges Following Positive Preclinical Data - Mira Pharmaceuticals (NASDAQ:MIRA)